A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

NCT04564027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumours

Interventions

DRUG: Ceralasertib

Sponsor

AstraZeneca